Netherton NOW
  • Home
  • About
    • About Netherton Syndrome
    • About Quoin Pharmaceuticals
  • Perspectives
    • Living with NS
    • Patient Experiences
  • Resources
  • Connect
Select Page

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Jan 6, 2025

Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label Study Demonstrated Clinical Benefits from QRX003 Observed Across All Measured Endpoints Before and After Dosing with QRX003 Photographs Available for...
Next Entries »

Featured News

April 2, 2025Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
March 25, 2025Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

All News

Subscribe

Get Netherton Syndrome Updates from Quoin

    This website does not provide medical advice and is for educational purposes only. Quoin Pharmaceuticals a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases NethertonNow and associated logo are trademarks of Quoin Pharmaceuticals.

    All information, documentation, data, photographs, and other content herein is the property of Quoin Pharmaceuticals, Inc. and its affiliates, and is protected by worldwide copyright laws. You may use this content only for your personal use for non- commercial purposes, and no modification or further reproduction of the content is permitted. The content may otherwise not be copied or used in any way without the express written permission of Quoin Pharmaceuticals, Inc.
    Copyright © 2025 Quoin Pharmaceuticals Inc.
    All rights reserved.
    Privacy PolicySitemap